Document Detail

Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease.
MedLine Citation:
PMID:  8023874     Owner:  NLM     Status:  MEDLINE    
Behçet's disease is a multisystem disorder that may cause profound ocular inflammation and blindness. We reviewed 19 patients with severe ocular Behçet's disease treated with combined cyclosporine and corticosteroid therapy. Previous treatment with corticosteroids alone failed to control the uveitis in all patients. Ten patients were given cyclosporine therapy alone (mean dosage, 8.6 mg/kg of body weight per day), and nine patients were given lower dosages of cyclosporine (mean dosage, 6.2 mg/kg of body weight per day) in combination with prednisone (mean dosage, 29.4 mg per day). The mean follow-up on therapy was 51 months. After three months of therapy, a trend toward greater improvement in visual acuity was noted in patients treated with combined cyclosporine and prednisone compared to those receiving cyclosporine alone (17.8 letters vs 10.2 letters, P = .2379), but after one year little difference was observed in the improvement between the two groups (5.8 letters vs 3.3 letters, P = .7984). However, a trend toward greater renal toxicity was seen in patients treated with cyclosporine alone after both three months and one year of therapy. Because of either a suboptimal therapeutic response or adverse effects, all patients treated with cyclosporine alone at baseline had prednisone added to their regimen after a mean time of 23.5 months. Overall, visual acuity remained stable or improved in 28 of 37 eyes (75.7%) over the course of therapy. These data suggest that combined cyclosporine and prednisone therapy is an effective treatment for Behçet's uveitis and may be less toxic than therapy with cyclosporine alone. A prospective, randomized trial with a larger sample size is needed to provide definitive data.
S M Whitcup; E C Salvo; R B Nussenblatt
Related Documents :
24141694 - Is the supine position superior to the prone position for percutaneous nephrolithotomy ...
7836864 - Low dose cyclosporin-a therapy in behçet's disease.
8390014 - Cyclosporin a: early or delayed onset by prophylactic immunosuppression?
23441774 - Activity and damage in granulomatosis with polyangiitis.
14997234 - Percutaneous closure of interatrial defects: the free state experience.
12021694 - Why insurers should reimburse for compression stockings in patients with chronic venous...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  American journal of ophthalmology     Volume:  118     ISSN:  0002-9394     ISO Abbreviation:  Am. J. Ophthalmol.     Publication Date:  1994 Jul 
Date Detail:
Created Date:  1994-08-01     Completed Date:  1994-08-01     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370500     Medline TA:  Am J Ophthalmol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  39-45     Citation Subset:  AIM; IM    
Clinical Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Behcet Syndrome / drug therapy*
Cyclosporine / adverse effects,  therapeutic use*
Drug Therapy, Combination
Follow-Up Studies
Glomerular Filtration Rate
Kidney / drug effects
Middle Aged
Prednisone / therapeutic use*
Uveitis / drug therapy*
Visual Acuity
Reg. No./Substance:
53-03-2/Prednisone; 59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Racial differences in the prevalence of atrophic-appearing macular lesions between black and white p...
Next Document:  A quantitative and cartographic study of retinal microvasculopathy in acquired immunodeficiency synd...